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Intestinal-type gastric cancer is preceded by gastritis and intestinal metaplasia. There is uncertainty regarding the stage at which
genetic alterations in the p53 gene occur. Reactive oxygen species (ROS) may participate in the production of mutations and the
inactivation of p53 is due to infection by the bacterium Helicobacter pylori. We have investigated whether alterations of the p53 gene
can be detected in gastritis and intestinal metaplasia using the restriction site mutation assay. We also assessed the potential
contribution of ROS to p53 inactivation using electron spin resonance spectroscopy (ESR) and correlated with the presence of H.
pylori. In all, 35% of the gastritis samples and 45% of the intestinal metaplasia samples were found to contain mutations in exons 5–8
of the p53 gene. Electron spin resonance spectroscopy analysis showed a significant increase in free radical levels in gastritis samples
compared with normal, intestinal metaplasia and cancer samples, suggesting that free radicals present in gastritis may contribute to
p53 mutations. There was no significant difference in free radical levels between the H. pylori-positive and -negative groups. However,
a small subpopulation of the H. pylori-negative patients had much higher levels of free radicals. This suggests a more prominent role
for other factors in ROS production.
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The p53 gene is the most frequently inactivated tumour suppressor
gene identified in human cancers to date (Han et al, 2002). Over
15000 p53 mutations have been documented from tumour and cell
line samples (www.iarc.fr), with loss of p53 function most
commonly induced through point mutation (Bates and Vousden,
1996). More than 30% of p53 mutations occur at methylated CpG
sites in codons 157, 175, 245, 248, 273 and 282 (Chen et al, 1998).
Thus, CpG sites frequently act as mutational hot spots, which
warrant their investigation to determine their potential role in
tumour aetiology. p53 gene mutations appear to be key factors in
the development of gastric cancer (Gomyo et al, 1996) having been
documented in more than 60% of the reported cancer cases
(Tamura et al, 1991). Classically, gastric cancer can be divided into
two histological subtypes: diffuse or intestinal (Lauren, 1965). The
intestinal type is believed to arise from a sequence of gastritis,
intestinal metaplasia and increasing grades of dysplasia. There is
controversy regarding the stage at which genetic alterations of the
p53 gene occur within the metaplasia – dysplasia sequence
(Uchino et al, 1993; Becker et al, 2000). p53 mutations detected
in gastritis have been documented by Stemmermann et al (1994)
and Kodama et al (1998), while studies by Zheng and YouYoung
(1998), Shiao et al (1994) and Ochiai et al (1996) show p53
alterations only in intestinal metaplasia. Mutations of p53 in early
gastric cancer have been found by Tohodo et al (1993) and Uchino
et al (1993), while Romitti et al (1998), Brito et al (1994) and
Joypaul et al (1993) claim that p53 mutations are late events in
gastric cancer. However, p53 alterations in these studies have been
detected using a variety of methods such as the polymerase chain
reaction (PCR), PCR – single-strand conformation polymorphism,
direct sequencing and immunohistochemistry. Thus, it appears
that the frequency and stage at which p53 alterations are detected
may depend on the methods used to detect them (Stemmermann
et al, 1994). To investigate the timing of p53 mutations in gastric
cancer, we employed the restriction site mutation (RSM) assay
(Myers and Parry, 1994). This method detects mutations at
restriction enzyme sites in human genes. Fortuitously, five of the
eight main p53 mutational hot spots (codons 175, 213, 248, 249 and
282) contain restriction sites and are amenable to RSM analysis in
patients with gastritis and intestinal metaplasia. Exhaustive
digestion of the target DNA followed by amplification of the
enzyme-resistant (mutated) sequences by PCR means that RSM is
capable of detecting low levels of mutations (one mutated sequence
among 10
4 –1 0
5 wild-type sequences) (Jenkins et al, 1999). This,
in turn, allows for the molecular selection of mutated samples and
makes mutation detection in premalignant samples feasible.
As the bacterium Helicobacter pylori (H. pylori) has been
implicated in gastric cancer progression through its induction
of inflammatory-mediated reactive oxygen species (ROS), we
assessed the H. pylori status of the patients using histology
and PCR-based analysis. In addition, the level of ROS present
in tissues representative of the different stages of the
metaplasia – dysplasia sequence was directly measured in a
separate cohort of gastric biopsies using electron spin resonance
(ESR) spectroscopy. Electron spin resonance spectroscopy is Received 21 February 2003; revised 14 July 2003; accepted 24 July 2003
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measuring free radicals in tissue and body fluids (Ashton et al,
1999; Berliner et al, 2001).
METHODS
Materials for ESR
Antral biopsy samples were taken from consenting patients
attending endoscopy. The ethical approval for this study was
granted by the Local Research Ethics Committee. Biopsies were
removed with standard gastric biopsy forceps and then cut in half
with sterile scalpel blades. Half the biopsy sample was sent for
histological examination, while the other was placed on ice for
transportation back to the laboratory, and then stored at  201C.
Frozen samples were also obtained from fresh gastrectomy
specimens. In total, 21 normal, 23 gastritis, 12 intestinal metaplasia
and 13 carcinoma samples were analysed.
Methods for ESR
A 140mmoll
 1 solution of the spin trap a-phenyl-tert butyl
nitrone (PBN) (Sigma-Aldrich, Dorset, UK) was freshly prepared
in sterile sodium chloride, and aliquoted into individual McCart-
ney bottles. To prevent photolytic degradation and the generation
of artefactual radicals, the PBN solution was kept in the dark and
placed on ice until use. Following collection of samples at
endoscopy, samples were weighed and then immediately incubated
in the spin trap agent PBN for approximately 2h at 371C in a water
bath. During this incubation, usually short-lived free radicals
present in the biopsy samples were collected and was stabilised by
the PBN solution. Organic extraction was carried out by adding the
PBN solution to an equal volume of HPLC grade toluene (Sigma-
Aldrich, Dorset, UK), which had been previously degassed for 2h.
The toluene/PBN solution was vortexed for 3min and then
centrifuged for 3min at 13000rpm to separate the organic layer.
The organic layer was then pipetted off into a new sterile
McCartney bottle (covered in foil), ready for analysis. The organic
layer containing the PBN adduct was transferred to a precision-
bore quartz ESR sample tube which was then vacuum degassed in a
freeze – pump – thaw procedure, using a turbo pump to 10
 3Torr
for three consecutive 5min cycles. The sample was then
immediately analysed at room temperature using a Bruker EMX
series X-band spectrometer at the University of Glamorgan,
Pontypridd, UK.
Materials for RSM
Biopsies for RSM were collected from a different cohort of patients
because the toluene used in ESR analysis degrades DNA rendering
it unsuitable for RSM analysis. Furthermore, whole biopsy samples
were needed to provide sufficient DNA for RSM analysis. Thus, in
the RSM study, paired biopsy samples were taken for DNA
extraction and histology. Paraffin-embedded archival material was
also used, which was obtained from the Histopathology Depart-
ment of Morriston Hospital, Morriston, Swansea. In total, 12
normal samples (two fresh, 10 archival), 20 gastritis samples (eight
fresh, 12 archival) and 20 intestinal metaplasia samples (six fresh,
14 archival) were analysed.
DNA extraction for RSM
DNA extraction from biopsy samples was carried out using a high
salt method (Stratagene, Cambridge, UK), while extraction of DNA
from archival material was carried out using the DNeasy tissue kit
(Qiagen, Crawley, UK).
RSM analysis
In total, 1mg of DNA, containing 3 10
5 copies of the p53 gene,
from gastritis, intestinal metaplasia and control samples (diluted
in 15ml of distilled H2O) was incubated with 2ml of the restriction
enzyme of interest, 2ml Taq polymerase thermo buffer (Promega
Corp., Southampton UK) supplemented with 1.25mM MgCl2,
overnight at the temperature optimum for enzymatic digestion.
Polymerase chain reaction was carried out on the digested DNA
samples by adding 15pmol of each designated primer, 2.5U of Taq
polymerase (Promega Corp.), 1 thermo buffer (Promega Corp.),
100mM of each dNTP (Promega Corp) and 1.5mM MgCl2 to each
tube, and the volume made to 50ml with H2O. Polymerase chain
reaction primers and restriction enzymes used were: forward,
50CCGCGCCATGGCCATCT; reverse, 50GCGCTCATGGTGGGGG
(Hha1) for exon 5, hot spot codon 175; forward, 50GTCCCCAGG-
CCTCTGATTCCTC; reverse, 50TAACCCCTCCTCCCAGAGACCC-
CAG (Taq1) for exon 6, hot spot codon 213; forward, 50ATGTG-
TAACAGTTCCTGCATGG; reverse, 50CTGACCTGGAGTCTTCCA-
GTG (Msp1/HaeIII) for exon 7 hot spots 248/249 and forward,
50CCTCTTGCTTCTCTTTTCCTATCC; reverse, 50CTTGGTCTCCT-
CCACCGCTTCTTG (Msp1) for exon 8, hot spot codon 282.
The thermal cycle consisted of a preincubation step of 2min
at 941C for complete denaturation of the DNA followed by
31 cycles (27 cycles for exon 7) at 941C for 30s, a specific
annealing temperature of 601C (exons 5, 7 and 8) or 651C
(exon 6) for 10s and an extension phase at 721C for 10s. After
PCR amplification, 16ml of PCR product was subjected to
a second round of digestion with 2ml of the appropriate
restriction enzyme and 2ml of enzyme-specific buffer overnight
at the recommended temperature to remove any remaining
wild-type DNA that may have escaped the initial digestion.
Restriction site mutation products were then electrophoresed
on 6 or 10% polyacrylamide gels (depending on the size of the
PCR product) using a Protean III electrophoresis system
(Biorad, Hemel Hempstead, UK) and stained with silver. Putative
enzyme-resistant samples were detected as undigested bands
corresponding to the same size as a positive (undigested) PCR
control.
Sequencing
Mutations detected by their resistance to enzyme digestion were
confirmed by sequencing. Resistant PCR products of exon 5
(71bp) and exon 7 (79bp), which were too small for direct
sequencing, were cloned into pCR2.1 plasmid vectors using a TA
cloning kit (Invitrogen Corp., The Netherlands) prior to sequen-
cing. Enzyme-resistant PCR products greater than 100bp were sent
for sequencing (Oswel, University of Southampton, UK). Only
mutations evident on both strands of the DNA were deemed as
clear positive results.
H. pylori detection
Detection of H. pylori infection for the samples used in the ESR
and RSM analysis was determined by histological examination by
the same pathologist to maintain consistency. In addition, H.
pylori infection in the gastritis samples, from the RSM study, was
confirmed by PCR using forward primer 50AAACCAATCG-
CTGTGAAACC and reverse primer sequences 50ACGGAA-
GGCTTTCTCTCACA to generate a 94bp fragment of the flagellin
gene. The thermal cycle consisted of a preincubation step of 2min
at 941C, 30 cycles at 941C for 30s, a specific annealing temperature
of 601C for 10s and an extension phase at 721C for 20s. Gastritis
samples identified as H. pylori positive were then subjected to
further PCR analysis for detection of the cag A gene. Primers for
the amplification of the cag A gene were synthesised according to
Lage et al (1995) and the thermal cycle was the same as above,
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(30s).
Statistical analysis
Data generated from the ESR samples were analysed using the
nonparametric Mann – Whitney U-test for two group comparisons
and the Kruskal – Wallis test and the Bonferroni procedures were
carried out for multiple group comparisons. Results were
considered statistically significant when Po0.05.
RESULTS
Electron spin resonance spectroscopy results
Table 1 shows the number of free radicals detected in the normal,
gastritis, intestinal metaplasia and tumour samples. The Kruskal –
Wallis test revealed a overall significant difference in the free
radical levels (P¼0.050) between all the groups. Two-group
comparisons revealed a significant difference in free radical levels
between gastritis and tumour samples and between normal and
tumour sample. However, after applying the Bonferroni procedure
the adjusted P-value required for significance was 0.008. This
meant a significant difference was found in free radical levels only
between gastritis and tumour samples, although an overall trend
towards increased free radical levels in the gastritis samples was
observed (Figure 1).
When the gastritis samples were subdivided into H. pylori-
positive and -negative groups, using histology, ESR analysis
revealed the levels of free radicals in the H. pylori-positive samples
to be at a similar level to those in the negative group (Table 2 and
Figure 2). Statistical analysis confirmed there was no significant
difference in the levels of free radicals between the two groups
(P¼0.948). Interestingly, a trend towards increased free radical level was observed in the H. pylori-negative samples. Electron spin
resonance spectroscopy analysis highlighted a subpopulation of
these patients as having much higher levels of free radicals than
those of the rest of the group or when in comparison to the H.
pylori-positive sample data. Furthermore, gastritis samples were
subdivided, again by histological examination, according to their
degree of acute and chronic inflammation (Table 3). A linear
multiple regression analysis was carried out on this data to
determine the extent to which acute or chronic inflammation (and
their respective severity) could explain statistically the variation in
free radical levels. No significant effect (P¼0.972) was found with
all variables in the equation. In addition, the R
2 value of 0.096
suggests that only a small proportion, if any, of the variation in
free radical levels could be explained by different grades of
inflammation.
Restriction site mutation results
No RSMs were detected in any of the p53 hot spot codons studied
from the 12 normal samples. Thus, mutations found in subsequent
samples were deemed to be genuine and not a result of
experimental error. Of the 20 gastritis samples analysed, 35% (7
out of 20) of the samples were resistant to restriction enzyme
digestion in one of the five codons studied, but eight mutations in
total were found upon sequencing (with one sample having a
double mutation in exon 7 at codons 249 and 250). Of the 20
intestinal metaplasia samples analysed, 45% (9 out of 20) of the
samples were found to be resistant to restriction enzyme digestion,
showing 11 mutations in total, with two samples containing a
double mutation (one sample had mutations at codons 248 and 250
of exon 7 and the other sample contained a double mutation at
codon 175 of exon 5 and codon 250 of exon 7) (Table 4). The
majority of the mutations were clustered at hot spot codons 248,
249 and 250 of exon 7 (five mutations at each codon).
Table 1 Mean number of radicals according to tissue type
Tissue type
No. of
samples
Mean no. of
radicals (10
3) s.d. s.e.
Normal 21 6.102 4.737 1.033
Gastritis 23 8.456 8.532 1.779
Intestinal
metaplasia
12 5.000 3.184 0.919
Cancer 13 3.361 1.489 0.413
0
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Figure 1 Mean number of radicals in precancerous and cancerous
gastric tissue detected by ESR spectroscopy.
Table 2 Mean number of radicals with regards to H. pylori status
Tissue type
No. of
samples
Mean no. of
radicals (10
3) s.d. s.e.
H. pylori
positive
8 5.350 1.567 0.554
H. pylori
negative
15 10.113 10.238 2.642
H.pylori negative H.pylori positive
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Figure 2 Free radical levels (10
3)i nH. pylori-positive and -negative
gastritis tissue.
p53 mutation detection
C Morgan et al
1316
British Journal of Cancer (2003) 89(7), 1314–1319 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yTypes of mutations detected by RSM
Of the 19 mutations detected in total, 15 were missense mutations
resulting in an amino-acid change. Six of these missense mutations
were detected in the gastritis samples and the remaining nine were
detected in intestinal metaplasia samples. Of these missense
mutations, one was a GC-TA transversion, two were AT-GC
transitions and 12 were GC-AT transitions, with six occurring at
CpG dinucleotides. The remaining four mutations were silent,
producing no amino-acid change (Table 4).
Detection of H. pylori infection
As H. pylori has been implicated in the gastritis stage of gastric
cancer progression, biopsies from patients with gastritis (within
the RSM study) were analysed by PCR to determine the subtype of
H. pylori present (specifically, the cag A virulence factor).
Table 5 shows the gastritis samples and their corresponding H.
pylori, cag A and p53 mutational status. Polymerase chain reaction
analysis revealed that 80% (16 out of 20) of these samples were
positive for H. pylori, which supports the current literature. From
the 16 samples shown to be positive for H. pylori infection, 44% (7/
16) were found to possess the cag A gene. Interestingly, six out of
the seven individuals found to have p53 mutations were H. pylori
positive. This suggests that H. pylori may be capable of causing p53
mutations in a subpopulation of individuals. Furthermore, the fact
that four out of the six samples positive for H. pylori infection and
p53 mutations also had the cag A gene would support the
hypothesis that strains possessing cag A are more virulent.
However, a contingency w
2 test showed no significant association
between p53 mutations, H. pylori status and cag A status was
observed (P¼0.439), presumably as a consequence of the low
numbers involved.
DISCUSSION
The identification of individuals at a high risk of progressing to
cancer offers promising possibilities for the prevention of cancer
(Hussain and Harris, 1996), and in most cases the outcome largely
depends on an early diagnosis (Matturri et al, 1998). However,
little is still known about the genetic events responsible for the
initiation and progression of gastric cancer (Koo et al, 2000; Sud
et al, 2001). We have used the RSM assay and the ESR technique to
analyse gastritis and intestinal metaplasia samples to address the
issue of whether genetic alteration of p53 is an early or late event in
gastric carcinogenesis, and to obtain a direct measure of free
radical levels (on separate tissue samples) at each stage in the
sequence of events leading to gastric cancer. As the H. pylori status
was also known for these patients, we have also been able to
correlate the H. pylori status with both the free radical load and the
presence of a p53 mutation. The hypothesis we have been testing
here is that H. pylori, and in particular those strains that possess
the cag A virulence gene, induces ROS in gastric tissue which
subsequently introduces genetic alterations (p53 mutations),
which drive gastric cancer progression.
The RSM assay has previously been shown to have a detection
limit of one mutated sequence in 10
 4 –1 0
 5 wild-type sequences
(Jenkins et al, 1999, 2001). Hence, this methodology is well suited
Table 3 Degree of inflammation in gastritis samples with regard to free
radical level
Patient no.
Acute
inflammation
Chronic
inflammation
No. of free
radicals (10
3)
3 0 1 2.9
62 3 6
10 1 3 7.3
12 1 2 4.2
15 0 2 8
20 2 1 4.6
22 0 1 25.3
27 0 1 16.8
35 0 1 4.5
39 0 1 2.3
40 0 1 37
41 0 1 14
47 0 1 5.3
52 2 3 4.7
55 0 1 2.5
58 0 1 14
59 0 1 3
60 0 1 2.5
61 0 1 2.6
63 0 1 4
64 0 1 4
67 3 2 14.3
69 0 1 4.8
Degree of inflammation: 0¼none, 1¼mild, 2¼moderate and 3¼severe.
Table 4 p53 mutations detected in gastritis and intestinal metaplasia (Im)
samples using RSM
Exon Codon Mutation Amino-acid change Histology
5 174 G-A Silent Gastritis
6 213 A-G Silent Gastritis
7 248 G-A Arg-Gln Gastritis
7 248 G-A Arg-Gln Gastritis
7 249 A-G Arg-Gly Gastritis
7 249 G-A Arg-Lys Gastritis
7 249 G-A Arg-Lys Gastritis
7 250 C-T Pro-Ser Gastritis
5 175 C-T Arg-Cys Im
7 247 C-T Silent Im
7 248 G-T Arg-Leu Im
7 248 G-A Arg-Gln Im
7 248 G-A Arg-Gln Im
7 249 A-G Arg-Gly Im
7 249 G-A Silent Im
7 250 C-T Pro-Ser Im
7 250 C-T Pro-Ser Im
7 250 C-T Pro-Ser Im
7 250 C-T Pro-Ser Im
Table 5 H. pylori, cag A and p53 mutational status of gastritis samples
Patient no. H. pylori +/  cag A +/  Mutation Codon
5+ + G C -AT 249/250
7+  
8+  
9+  
12    AT-GC 249
13 +  
24 + + GC-AT 248
25 + +
28 +   GC-AT 174
30 +   GC-AT 249
34 +  
71 + + AT-GC 213
72 +  
73 + +
74 + + GC-AT 248
75 + +
76 +  
77   
78   
79   
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mutations. p53 mutations were found in 0% of controls, 35% of
gastritis samples and 45% of intestinal metaplasia samples. Of the
19 mutations detected in total, 63% (12 out of 19) were located at
codons regarded as mutational hot spots by the IARC database
(codons 175, 213, 248 and 249) and 15 were missense mutations
resulting in amino-acid substitutions. The detection of p53 gene
mutations in gastritis and intestinal metaplasia indicates that
genetic alterations of p53 can be an early event in the pathogenesis
of gastric cancer, and suggests that this approach may be suitable
for detecting them. The types of p53 mutations (mainly GC-AT
transitions) further suggest a role of ROS, which are known to
favour such mutation types (Moraes et al, 1990; Feig et al, 1994;
Purmal et al, 1994; Jenkins et al, 2001).
In an attempt to correlate the stage at which p53 mutations
occur with the stage of cancer progression, ESR spectroscopy was
used. In this separate study, there was a significantly increased
level of free radicals in gastritis samples compared with normal,
intestinal metaplasia and cancer. This is consistent with the
hypothesis that ROS generated in inflamed tissue may be
important in carcinogenesis. It is known that polymorphonuclear
leucocytes can produce ROS during host defence reactions such as
that associated with the bacterium H. pylori. When the gastritis
samples were subdivided into H. pylori-positive and -negative
samples, and their free radical levels compared, no significant
difference in free radical levels was found. Furthermore, there was
also no correlation between degree of inflammation and free
radical levels. Interestingly, however, a small population of the
samples within the H. pylori-negative group was shown to exhibit
much higher levels than the rest of the group. This suggests a
potential role for factors other than H. pylori, or even severity of
gastric inflammation, to be the primary cause of ROS generation in
gastric tissue and highlights this subpopulation as an interesting
group in which to carry out further investigations.
The gastritis samples from the p53 study were also analysed to
determine whether there was any relationship with H. pylori
infection and the cag A virulence factor. No significant difference
was shown to exist between samples in terms of their H. pylori and
p53 mutational status. Nevertheless, p53 mutations were found in
seven individuals, six of whom were positive for H. pylori
infection, with four out of the six being cag A positive. This
suggests that H. pylori infection (and subtype) may play a role in
inducing mutations in the p53 gene. Therefore, this result may
provide evidence for a causal relationship between ROS-induced
mutations of p53 in inflamed tissue as a result of H. pylori
infection, but only in certain individuals.
Here we have shown, using two different cohorts of patients,
that p53 mutations are detectable in gastritis and that this stage
also shows the highest levels of ROS. Our findings have also shown
that although no significant difference in free radical levels were
observed between H. pylori-infected and noninfected samples, the
bacterium may contribute to genomic instability (shown here by
the presence of p53 mutations), but only in a subpopulation of
individuals. Thus, the exact role of H. pylori in the sequence of
events leading to gastric cancer still remains to be elucidated.
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